Support teaching, research, and patient care.
Dr. Taia Wang is an Assistant Professor of Medicine and of Microbiology and Immunology with research aimed at defining mechanisms in human immunity and disease. The Wang laboratory uses in vivo and in vitro systems to study how antibodies can modulate viral infections or anti-viral vaccine responses through signaling interactions with Fc gamma receptors (FcγRs). The overarching goal of projects in the Wang lab is to elucidate FcγR pathways that can be harnessed towards the development of enhanced vaccines and therapeutics. Dr. Wang obtained M.D. and Ph.D. training at Mount Sinai School of Medicine. Her Ph.D. training focused on mechanisms in immunity against influenza viruses (P. Palese). Following this training, she completed postdoctoral research at the Rockefeller University where she studied human IgG and FcγR biology in the Laboratory of Molecular Genetics and Immunology (J. Ravetch). During this time she also undertook formal training in clinical research, earning a Masters of Science in Clinical Investigation at The Rockefeller University. The Wang laboratory's work on viral immunity and disease pathogenesis has been recognized with several awards including the Searle Scholar’s Award and the Burroughs Wellcome Fund Investigator Award for Investigators in the Pathogenesis of Infectious Disease. Dr. Wang is also the recipient of a Bravo Family Junior Faculty Endowment.SARS-CoV-2, dengue viruses, influenza viruses, disease pathogenesis, influenza virus vaccines
Major goal: To define how IgG Fc glycoforms are regulated in vivo.
Major goal: To define the role of FcγRIIIa in antibody-dependent enhancement of dengue infections.
Major goal: To define Fc-Fc receptor interactions that are essential for immunity against influenza and dengue viruses.
Major goal: This work will define mechanisms for enhancing the durability of passive immunization of neonates
Impact of Initial Influenza Exposure on Immunity in Infants
Major Goals: To define the role of antibodies in broad protection against influenza viruses
Major Goals: PROJECT 3: To determine whether specific forms of IgG antibodies predispose to severe dengue disease during infection.
Major Goals: Defining adaptive and innate immunity, memory and repertoire in vaccination and infection
Laboratory of Mechanisms in Human Immunity and Disease PathogenesisAntibodies are a critical component of host defense. While the importance of humoral immunity has been recognized for decades, substantial gaps in knowledge remain around how antibodies function, and how their function is regulated, in vivo. Our laboratory performs studies designed to fill in these gaps, with the goal of enabling new vaccine and therapeutic strategies to prevent human disease. My interest in this area culminated from training in medicine, RNA virus biology (PhD), and molecular antibody biology (postdoctoral training). The intersection of these topics, viral immunity and disease pathogenesis, is the focus of our work. The essential question driving our research is why a small subset of people develop severe or fatal disease during viral infection while most infections result in a subclinical or mild outcome, even in at-risk populations. Our hypothesis is that the antibody signaling pathways that are engaged during viral infection through Fc gamma receptors (FcγRs) are a key driver of these distinct outcomes. We are focused on several major unknowns to address this hypothesis: How are antibody effector functions regulated in vivo and does this change in disease? How do distinct signaling pathways engaged by IgG immune complex-FcγR interactions impact host cell genetic regulation and the ultimate inflammatory/immune response? What are the tissue-specific functions that antibodies engage? How does the heterogeneity in post-translational modifications (PTMs) of human antibodies contribute to heterogeneity in viral immunity?Current clinical studies:Recruiting:An Open Label Study of IgG Fc Glycan Composition in Human ImmunityPrincipal Investigator: Taia T. Wang, MD, PhDClinicalTrials.gov Identifier:NCT01967238